Welcome: Nanjing Machido Pharmaceutical Technology Co., Ltd.
  • Voglibose CAS 83480-29-9
  • Voglibose CAS 83480-29-9
  • Voglibose CAS 83480-29-9
  • Voglibose CAS 83480-29-9
  • Voglibose CAS 83480-29-9
Voglibose CAS 83480-29-9 Voglibose CAS 83480-29-9 Voglibose CAS 83480-29-9 Voglibose CAS 83480-29-9 Voglibose CAS 83480-29-9

Voglibose CAS 83480-29-9

  • Voglibose CAS 83480-29-9
  • CAS No: 83480-29-9
  • Molecular Formula: C10H21NO7
  • Molecular Weight: 267.28
  • MDL NO: MFCD00865496

Product Details

Product Description:

Product Name: Voglibose CAS NO: 83480-29-9




Chemical & Physical Properties:

Appearance : white to off-white crystalline powder

Assay :NLT99.0%

Boiling Point: 601.9℃ at 760 mmHg

Flash Point: 274.1℃

Melting Point: 162.0℃~163℃

Density:1.58 g/cm3

Refractive Index: 1.635

Vapor Pressure: 0mmHg at 25°C

PSA: 153.64000

LogP: -2.36

Solubility: Water (Slightly)

Category: Standards; Pharmaceutical/API Drug Impurities/Metabolites;

Safety Information:

RTECS: NM7524600

Safety Statements: S36/37

Risk Statements: R20/21/22

Hazard Codes: Xi

HS Code: 2933990090

Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.

Application: An α-Glucosidase inhibitor used as an antidiabetic.

D-epi-Inositol,3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl) wave of sugar is an oral fall blood sugar medicine, postprandial hyperglycemia can improve diabetes. Voglibose wave sugar applicability is wide and is not only applicable to middle-aged and old people with diabetes, for refractory patients with type 2 diabetes, patients with secondary failure to sulfonylureas, hyperlipidemia of diabetic patients, the combining cardio-cerebral blood tube disease of diabetic patients, merging, hyperinsulinemia have remarkable curative effect. Since this product does not stimulate the secretion of insulin, it can reduce the harmful effects of postpranational hyperinsulinemia, reduce insulin resistance, and be beneficial to the prevention and treatment of metabolic syndrome such as cardiovascular complications.

Our factory manufacture’s Voglibose CAS 83480-29-9, mature technology, stable output, quality assurance.

Delivery deadline: from stock

We can provide 2,3-Dideoxy-2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-4-C-(hydroxymethyl)-epi-inositol COA, N-(1,3-Dihydroxy-2-propyl)valiolamine MOA, ROS, (1S,2S,3R,4S,5S)-5-[(1,3-Dihydroxy-2-propanyl)amino]-1-(hydroxymethyl)-1,2,3,4-cyclohexanetetrol MSDS and other support for you !

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.

Scan Our Wechatclose
Scan Our Wechat